Antibodies to T cells in patients with systemic lupus erythematosus can induce antibody-dependent cell-mediated cytotoxicity against human T cells

The Journal of Clinical Investigation
S KumagaiI Green

Abstract

Patients with active systemic lupus erythematosus (SLE) often have circulating antibodies to T cells. These patients also often have leukopenia and diminished numbers of T lymphocytes. In addition, certain T lymphocyte functions are frequently impaired in patients with SLE. It has been previously considered that a complement-dependent cytotoxic mechanism was responsible for the above observations. We now demonstrate that antibody-dependent cell-mediated cytotoxicity (ADCC), a cytotoxic reaction mediated by antibody and effector cells in the absence of complement, can also kill T cells from normal individuals as well as from patients with SLE. Moreover, this ADCC could be observed using the plasma, effector cells, and target cells all obtained from the same individual with SLE. Plasma of those patients with active SLE, and in whom anti-T cell antibodies could be demonstrated by the more classical complement-dependent cytotoxicity, was most often able to mediate such an ADCC reaction. The IgG fraction of the plasma was responsible for inducing ADCC, and aggregated IgG could block the reaction. The fact that the IgG fraction was often more effective than the unfractionated plasma suggested that immune complexes present in SLE plas...Continue Reading

References

Jul 1, 1976·The Journal of Clinical Investigation·J L FeldmannN Talal
Sep 1, 1978·The Journal of Clinical Investigation·J J TwomeyA D Steinberg
Oct 1, 1978·The Journal of Clinical Investigation·A Sagawa, N I Abdou
Jan 1, 1978·Vox Sanguinis·B S HandwergerS D Douglas
Nov 2, 1976·The Journal of Experimental Medicine·B WåhlinP Perlmann
Jan 1, 1976·International Archives of Allergy and Applied Immunology·F P QuismorioB Harding
May 1, 1974·Cellular Immunology·M A Scheinberg, E S Cathcart
Jul 1, 1971·Proceedings of the National Academy of Sciences of the United States of America·T Shirai, R C Mellors
Oct 1, 1970·The New England Journal of Medicine·P I TerasakiE V Barnett

❮ Previous
Next ❯

Citations

Jan 1, 1982·Springer Seminars in Immunopathology·J W Goding
Feb 1, 1982·Journal of the American Academy of Dermatology·C M Lapiere
Dec 1, 1990·Immunological Reviews·A D SteinbergD M Klinman
Apr 1, 1982·The Journal of Clinical Investigation·K OkudairaR C Williams
Mar 1, 1984·The Journal of Clinical Investigation·C MorimotoS F Schlossman
Sep 1, 1990·The Journal of Clinical Investigation·A M Krieg, A D Steinberg
Jan 1, 1993·Virchows Archiv. B, Cell Pathology Including Molecular Pathology·T KhavkinD Testa
Aug 30, 2014·Translational Research : the Journal of Laboratory and Clinical Medicine·Chau-Ching LiuJoseph M Ahearn
Apr 1, 1981·International Journal of Dermatology·J D Taurog, A D Steinberg
Apr 1, 1992·Clinical Immunology and Immunopathology·J B Winfield, T Mimura
Dec 1, 1987·Clinical Immunology and Immunopathology·B S EdwardsC L Hoffman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.